Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Clinical guideline

NICE re-evaluates heart failure prescribing practices

The National Institute for Health and Care Excellence says the traditional practice of giving opioids to acute heart failure patients has limited clinical benefit.

National Institute for Health and Care Excellence (NICE) questions common prescribing practices when patients with acute heart failure are admitted to hospital

Source: MedicImage / Alamy

Acute heart failure is responsible for more than 67,000 annual hospital admissions in England and Wales

Updated national guidance on the management of acute heart failure has called into question some common prescribing practices that happen when this group of patients are admitted to hospital.

The National Institute for Health and Care Excellence (NICE) says the traditional practice of giving opioids to patients to relieve their stress has limited clinical benefit. The best way to manage this is through “rapid diagnosis, initiation of treatment and a safe, reassuring environment”, it says.

In developing its clinical guideline, published on 8 October 2014, NICE also considered which diuretic strategy has the best outcomes. Although diuretics are usually given intravenously, there is “significant” variation in doses and whether they are given as continuous infusions or as intermittent boluses. Based on the evidence, the guideline development group concluded that neither option is superior and the decision should depend on “clinical circumstances”.

NICE recommends that nitrates should not be routinely offered to people with acute heart failure because the clinical benefits are unclear. If nitrates are used in specific circumstances, such as for people with concomitant myocardial ischaemia or severe hypertension, blood pressure must be monitored closely, it says.

The guidance states there is “no sustained benefit” from routinely offering inotropes or vasopressors to people with acute heart failure, even though this is common practice. Use of these agents should be limited to stabilising a patient in cardiogenic shock.

NICE gives recommendations for the timing of beta-blocker therapy after a patient has stabilised and the circumstances in which treatment should be reintroduced or started from scratch.

Recommendations for best practice for when angiotensin-converting enzyme inhibitors should be prescribed are also outlined.

NICE recommends that people with acute or suspected acute heart failure should be assessed by a specialist multidisciplinary team. A member of the team should be responsible for a follow-up visit to the patient two weeks after he or she has been discharged from hospital. The team should be part of a hospital’s cardiology ward, deliver the patient’s ongoing care and be prepared to do outreach work, according to NICE.

Acute heart failure is responsible for more than 67,000 annual hospital admissions in England and Wales and is the leading cause of hospital admission in people aged over 65 years.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066751

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.